Associated Papers
Multimodal scanning of genetic variants with base and prime editing.
Belli O et al.
Nature Biotechnology, 2025
Predicting Resistance to Small Molecule Kinase Inhibitors.
Nagarajan A et al.
Journal of Chemical Information and Modeling, 2025
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK et al.
Nature Communications, 2024
38548752 (PubMed )
Supplement: 41467_2024_45594_MOESM4_ESM.xlsx › All
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S8
Comparison of mutation profile between primary phyllodes tumors of the breast and their paired local recurrences.
Mitus J et al.
Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists, 2020
Effects of Single Nucleotide Polymorphisms on the Binding of Afatinib to EGFR: A Potential Patient Stratification Factor Revealed by Modeling Studies.
Kannan S et al.
Journal of Chemical Information and Modeling, 2019
Altered conformational landscape and dimerization dependency underpins the activation of EGFR by αC-β4 loop insertion mutations.
Ruan Z et al.
Proceedings of the National Academy of Sciences of the United States of America, 2018
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Ruan Z et al.
Biochemistry, 2017
Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships.
Goyal S et al.
Bmc Genomics, 2015
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2009
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
Avizienyte E et al.
The Biochemical Journal, 2008
18588508 (PubMed )
Supplement: supplement_1.pdf
Select a paper to view details